Christine Cho , Ciara Marshall , Erik Washburn , Edward Podczaski , Joel Sorosky , Shaina Bruce
{"title":"Low mitotic count may affect the prognosis of uterine leiomyosarcoma: A report of two cases","authors":"Christine Cho , Ciara Marshall , Erik Washburn , Edward Podczaski , Joel Sorosky , Shaina Bruce","doi":"10.1016/j.gore.2025.101766","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Uterine leiomyosarcoma (uLMS) is characterized by its aggressive nature, early metastatic potential, and poor clinical outcomes. Diagnosis of uLMS requires two out of the following three diagnostic criteria: marked cytologic atypia, 10 mitoses per 10 high power fields, tumor cell necrosis. This case series presents two cases of uLMS with a low mitotic rate and an indolent disease course, with excellent response to hormone therapies.</div></div><div><h3>Case 1</h3><div>A 44-year-old female was diagnosed with uLMS following a supracervical hysterectomy in 2006. The primary tumor demonstrated tumor cell necrosis, cytologic atypic, and 6 mitoses per 10 HPF. Her 18-year disease course is notable for four debulking surgeries and multiple courses of hormonal therapy resulting in durable responses.</div></div><div><h3>Case 2</h3><div>A 75-year-old female was diagnosed with smooth muscle tumor of uncertain malignant potential (STUMP) status post debulking surgery which was revised to leiomyosarcoma following lung biopsy confirmation of metastasis. The primary tumor and lung biopsy demonstrated tumor cell necrosis, cytologic atypia and 2 mitosis per 10 HPF. She demonstrated stable disease on letrozole for 11 months.</div></div><div><h3>Discussion</h3><div>These cases demonstrate that uLMS with low mitotic activity may exhibit less aggressive behavior than typical high-grade sarcomas. Recognizing this distinction can guide prognostication and treatment selection.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"59 ","pages":"Article 101766"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925000918","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Uterine leiomyosarcoma (uLMS) is characterized by its aggressive nature, early metastatic potential, and poor clinical outcomes. Diagnosis of uLMS requires two out of the following three diagnostic criteria: marked cytologic atypia, 10 mitoses per 10 high power fields, tumor cell necrosis. This case series presents two cases of uLMS with a low mitotic rate and an indolent disease course, with excellent response to hormone therapies.
Case 1
A 44-year-old female was diagnosed with uLMS following a supracervical hysterectomy in 2006. The primary tumor demonstrated tumor cell necrosis, cytologic atypic, and 6 mitoses per 10 HPF. Her 18-year disease course is notable for four debulking surgeries and multiple courses of hormonal therapy resulting in durable responses.
Case 2
A 75-year-old female was diagnosed with smooth muscle tumor of uncertain malignant potential (STUMP) status post debulking surgery which was revised to leiomyosarcoma following lung biopsy confirmation of metastasis. The primary tumor and lung biopsy demonstrated tumor cell necrosis, cytologic atypia and 2 mitosis per 10 HPF. She demonstrated stable disease on letrozole for 11 months.
Discussion
These cases demonstrate that uLMS with low mitotic activity may exhibit less aggressive behavior than typical high-grade sarcomas. Recognizing this distinction can guide prognostication and treatment selection.
期刊介绍:
Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.